Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P01857

UPID:
IGHG1_HUMAN

ALTERNATIVE NAMES:
Ig gamma-1 chain C region; Ig gamma-1 chain C region EU; Ig gamma-1 chain C region KOL; Ig gamma-1 chain C region NIE

ALTERNATIVE UPACC:
P01857; A0A0A0MS08

BACKGROUND:
Immunoglobulin heavy constant gamma 1 (IGHG1) is integral to humoral immunity, mediating effector functions of IgG on monocytes and triggering ADCC of virus-infected cells. It is part of a broader system where B lymphocytes produce membrane-bound or secreted glycoproteins, known as antibodies, that specifically bind antigens, leading to the antigen's elimination. The antigen-binding site's unique affinity for specific antigens is a result of somatic hypermutations and V-(D)-J rearrangement processes.

THERAPEUTIC SIGNIFICANCE:
The link between IGHG1 and multiple myeloma highlights its potential as a therapeutic target. Multiple myeloma, characterized by bone pain, hypercalcemia, and anemia, involves chromosomal aberrations in IGHG1. These genetic variations play a crucial role in the disease's onset and progression. Targeting the molecular mechanisms involving IGHG1 could lead to innovative treatments for multiple myeloma and related plasma cell disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.